Kestrel

NEYPPC Pharmacy - Unlicensed Parenteral Nutrition

Leeds Teaching Hospitals NHS Trust · published Thu 12 Nov 2026

In plain English

Reading the notice and writing a summary. This takes a few seconds the first time.

Who holds it now

Last won by Alliance Healthcare and AAH Pharmaceuticals Limited and Phoenix Healthcare and 1 more in Oct 2026, for £2.4bn.

What you're up against

  • The same firms have won it the last 2 times: expect them to bid again, and to know the work well.
  • 11 different firms won this buyer's 3 awards for this kind of work in 2026.
  • It last went for £2448m in 2026.
  • The last award named 4 suppliers: it may be a framework, where many firms are chosen.

From Leeds Teaching Hospitals NHS Trust's earlier award notices for the same kind of work. The tender documents usually say which contract this one replaces.

The notice doesn't say where the documents are, but Leeds Teaching Hospitals NHS Trust's other tenders use health-family.force.com. Register there (it's free) and look for this tender, or email the buyer's contact on the notice.

The notice as published

The North East and Yorkshire NHS Pharmaceutical Purchasing Consortium intends to establish a Framework Agreement for the supply of Unlicensed Parenteral Nutrition (PN). The requirement will provide Participating Authorities with access to a range of aseptically prepared parenteral nutrition products supplied in ready-to-administer presentations. Products may include standardised batch-manufactured formulations alongside bespoke formulations manufactured to meet specific organisational or individual patient requirements. The scope of the Framework Agreement is expected to include multi-chamber parenteral nutrition bags with additions, lipid bags and syringes, batch-manufactured Trust-specific formulations, named-patient formulations, and paediatric and neonatal starter bags. Products supplied under the Framework Agreement will be unlicensed medicines and suppliers will be required to hold all relevant licences, authorisations and regulatory approvals necessary for their manufacture and supply within the United Kingdom, together with appropriate quality management, quality assurance and batch release arrangements. The Framework Agreement will provide participating NHS organisations with access to a suitable range of parenteral nutrition products, supporting continuity and resilience of supply, product quality, patient safety, regulatory compliance and value for money.